Teva CEO Urges Faster FDA Approvals Amidst NIH Workforce Cuts

Teva Pharmaceuticals' CEO advocates for quicker FDA generic drug approvals, which he argues would save the U.S. healthcare system money. Concurrently, the Trump administration has revised the number of layoffs at the National Institutes of Health to 1,165, affecting some staff who will be on administrative leave.

The CEO of Teva Pharmaceuticals, Richard Francis, has called on President Donald Trump's administration to expedite the approval process for generic drugs. Francis argues that quicker approvals by the FDA could lead to significant savings in the U.S. healthcare system.

Francis voiced his concerns during a news conference, stating that the FDA currently lacks the speed necessary for bringing more generics to market promptly. He emphasized the potential financial benefits of increased access to generic drugs for Americans.

In related news, an internal email from the National Institutes of Health revealed that the Trump administration has revised its layoff figures, now affecting 1,165 employees. The email indicated some adjustments to the initial list of layoffs, with administrative leave starting for affected staff on Monday.

(With inputs from agencies.)